Kush M. Parmar, MD, PhD is a managing partner at 5AM Ventures. Kush serves as a Director on the Boards of Akouos (NASDAQ: AKUS), Ensoma, Entrada (NASDAQ: TRADA), GlycoEra, Homology (NASDAQ: FIXX), and Rallybio. He previously served as acting Vice President of Strategy and Corporate Development at Novira (acquired by J&J) and served as Board Member or Observer for Achaogen (NASDAQ: AKAO), Arvinas (NASDAQ: ARVN) Audentes (NASDAQ: BOLD), Envoy (acquired by Takeda), and scPharmaceuticals (NASDAQ: SCPH). Kush serves on the Advisory Boards of Penn Medicine, Princeton University’s Department of Molecular Biology, and the Grace Science Foundation. He is a fellow of the Society of Kauffman Fellows. Prior to 5AM, Kush was at Harvard Medical School, where he was an NIH-sponsored MD/PhD Physician Scientist Fellow in the Harvard-MIT Health Sciences and Technology Program. He completed clinical clerkships at the Massachusetts General Hospital and Brigham and Women’s Hospital. At Princeton University, he worked on developmental genetics with Eric F. Wieschaus (Nobel Prize in Medicine in 1995). He holds a BA in molecular biology and medieval studies from Princeton University, a PhD in experimental pathology from Harvard University, and an MD from Harvard Medical School. Kush is based in 5AM Ventures’ Boston, MA office.